Enrico Derenzini, Vittorio Stefoni, Cinzia Pellegrini, Maria Paola Fina, Alessandro Broccoli, Filippo Venturini, Letizia Gandolfi, Stefano A Pileri, Maurizio Martelli, Maria Concetta Petti, Alessio Perrotti, Amalia De Renzo, Francesco Zaja, Michele Baccarani, Pier Luigi Zinzani
Young patients (aged 18-60 years) with good-prognosis diffuse large B-cell lymphoma (DLBCL) [0 and 1 risk factor according to age-adjusted international prognostic index (aa-IPI)] are distinguished from patients with poor-prognosis. Six cycles of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in combination with rituximab achieved best results in young patients with low-risk DLBCL. We retrospectively analyzed the data of 82 patients (18-60 years) with untreated aa-IPI 0-1 DLBCL, from six Italian institutions, who underwent, between January 2002 and January 2007, rituximab-cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone (R-MACOP-B) therapy followed, in patients with bulky presentation, by 30-36 Gy involved-field radiation therapy (34 patients)...
November 2009: Leukemia & Lymphoma